Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática
Tóm tắt
Từ khóa
Tài liệu tham khảo
Gisbert, 1999, ¿Son todos los H. pylorimalos?, Rev Esp Enferm Dig, 91, 508
Gisbert, 1997, Helicobacter Pyloriy úlcera duodenal: ¿relación causal o mera asociación?, Rev Clin Esp, 197, 693
Mégraud, 1998, Epidemiology and mechanisms of antibiotic resistance in Helicobacter Pylori, Gastroenterology, 115, 1278, 10.1016/S0016-5085(98)70101-5
Mégraud, 1999, Resistance of Helicobacter Pylorito antibiotics: the main limitation of current proton-pump inhibitor tripe therapy, Eur J Gastroenterol Hepatol, 11, 35
Glupczynski, 1999, Antibiotic susceptibility of H. pyloriin Europe in 1998; results of the third multicentre study, Gut, 45, 105
López-Brea, 1991, Susceptibility of Helicobacter Pylorito metronidazole, Eur J Clin Microbiol Infect Dis, 10, 1082, 10.1007/BF01984937
Gisbert, 1995, Efecto de la «triple terapia» sobre la erradicación de Helicobacter Pyloriy la cicatrización de la úlcera duodenal. Estudio inicial y a los 6 meses, Rev Esp Enferm Dig, 87, 193
Gisbert, 1996, ¿De qué factores depende el éxito de la triple terapia, «clásica » en la erradicación de Helicobacter Pylori?, Rev Esp Enferm Dig, 88, 317
López-Brea, 1997, Evolution of resistance of metronidazole and clarithromycin in Helicobacter Pyloriclinical isolates from Spain, J Antimicrob Chemother, 40, 279, 10.1093/jac/40.2.279
Garrido, 1998, Erradicación mediante triple terapia de Helicobacter Pylorien pacientes ulcerosos: papel de la endoscopia y sensibilidad anbitiótica, Enferm Infecc Microbiol Clin, 16, 471
Forné, 1998, Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter Pyloriinfection and duodenal ulcer healing, Am J Gastroenterol, 93, 35, 10.1111/j.1572-0241.1998.035_c.x
López Bartolomé, 1998, Diagnóstico microbiológico de Helicobacter Pyloriy su resistencia a los antimicrobianos, Rev Clin Esp, 198, 420
García Díaz, 1999, Resistencia antibiótica de H. pylorien Sevilla, Gastroenterol Hepatol, 22, 552
De la Veja, 1999, Evolución de las resistencias primarias de Helicobacter Pylori, Gastroenterol Hepatol, 22, 552
Ferrero, 1999, Análisis de la resistencia de Helicobacter Pyloria antibióticos en nuestro medio, Gastroenterol Hepatol, 22, 552
Pérez-Trallero, 1999, How long for the routine Helicobacter Pyloriantimicrobial susceptibility testing? The usefulness of the string test to obtain Helicobacter for culture, Am J Gastroenterol, 94, 3075, 10.1111/j.1572-0241.1999.3075_e.x
Ducóns, 1999, Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter Pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer, Aliment Pharmacol Ther, 13, 775, 10.1046/j.1365-2036.1999.00549.x
López-Brea, 1999, Metronidazole resistance and virulence factors in Helicobacter Pylorias markers for treatment failure in a paediatric population, FEMS Immunol Med Microbiol, 24, 183, 10.1016/S0928-8244(99)00024-3
De la Vega, 1998, Influencia de la resistencia al metronidazol en la erradicación del Helicobacter Pylori, Rev Esp Enferm Dig, 90, 27
López-Brea, 1998, Clarithromycin resistance in Helicobacter Pylori as a marker for treatment failure in a pediatric population, Gut, 43, 75
1992, European Study Group on Antibiotic Susceptibility of Helicobacter PyloriResults of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter Pylori, Eur J Gastroenterol Hepatol, 11, 181
Lind, 1999, The MACH2 study: role of omeprazole in eradication of Helicobacter Pyloriwith 1-week triple therapies, Gastroenterology, 116, 248, 10.1016/S0016-5085(99)70119-8
Wissfeld, 1997, Geographical distribution in the United States of primary resistance to clartithromycin and metronidazole in patients infected with Helicobacter Pylori, Gastroenterology, 112, A328
Graham, 1998, Antibiotic resistance in Helicobacter Pylori: implications for therapy, Gastroenterology, 115, 1272, 10.1016/S0016-5085(98)70100-3
Rautelin, 1992, Role of metronidazole resistance in therapy of H. pyloriinfection, Antimicrob Agent Chemother, 36, 163, 10.1128/AAC.36.1.163
Glupczynski, 1991, Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter Pylori, J Clin Microbiol, 29, 2072, 10.1128/JCM.29.9.2072-2075.1991
Hirschl, 1993, Comparison of three methods for the determination of the sensitivity of H. pylorito metronidazole, J Antimicrob Chemoter, 32, 45, 10.1093/jac/32.1.45
Piccolomini, 1997, Comparative evaluation of the E test, agar dilution and broth microdilution for testing susceptibilities of Helicobacter Pyloristrains to 20 antimicrobial agents, J Clin Microbiol, 35, 1842, 10.1128/JCM.35.7.1842-1846.1997
Midolo, 1995, Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter Pylori, Diagn Microbiol Infec Dis, 21, 135, 10.1016/0732-8893(95)00066-J
Midolo, 1997, Antimicrobial resistance testing of Helicobacter Pylori: a comparison of E-test and disk diffusion method, Pathology, 29, 411, 10.1080/00313029700169415
Alarcón, 1997, Discrepancies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter Pylori, J Clin Microbiol, 36, 1165, 10.1128/JCM.36.4.1165-1166.1998
Vakil, 1998, Clarithromycin-resistant Helicobacter Pyloriin patients with duodenal ulcer in the United States, Am J Gastroenterol, 93, 1432, 10.1111/j.1572-0241.1998.455_t.x
Broutet, 1998, Survey of the in vitro susceptibility of Helicobacter Pylorito antibiotics in France. Preliminary results, Gastroenterology, 14, A81, 10.1016/S0016-5085(98)80328-4
Glupczynski, 1998, Microbiological and serological diagnostic test for Helicobacter Pylori: an overview, Br Med Bull, 54, 175, 10.1093/oxfordjournals.bmb.a011668
Van Zwet, 1996, Prevalence of primary Helicobacter Pyloriresistance to metronidazole and clarithromycin in the Netherlands, Eur J Clin Microbiol Infect Dis, 15, 861, 10.1007/BF01691216
López-Brea, 1996, Metronidazole and clarithromycin susceptibility amongst H. pyloriclinical isolates from different Spanish regions, Gut, 39, 13
De Koster, 1997, Helicobacter Pyloriresistance to macrolides increases, to imidazoles remains stable, Gastroenterology, 112, A99
Wolle, 1999, No progression of primary metronidazole and clarithromycin resistance in clinical isolates of Helicobacter Pyloriin Germany, Gut, 45, 122
Glupczynski, 1998, Evolution of H. pyloriprimary resistance to antimicrobial agents in Belgium between 1995 and 1998, Gut, 43, 159
Glupczynski, 1995, Surveillance of Helicobacter Pyloriresistance to antimicrobial agents in Belgium from 1989 to 1994, Gut, 37, 56
De Koster, 1999, A nine years surveillance of H. pyloriresistance to macrolides and imidazoles, Gut, 45, 5
Villar, 1998, Evolución de la resistencia antimicrobiana de Helicobacter Pylori, Rev Esp Enferm Dig, 90, 162
De Koster, 1996, Six years resistance of Helicobacter Pylorito macrolides and imidazoles, Gut, 39, 5
Van der Wouden, 1997, Rapid increase in the prevalence of metronidazole-resistant Helicobacter Pyloriin the Netherlands, Emerg Infect Dis, 3, 385, 10.3201/eid0303.970320
Birac, 1999, Six year follow-up of resistance to antibiotics of Helicobacter Pyloriin Bordeaux, France, Gut, 45, 107
Llor, 2000, ¿Utilizamos de forma razonada los macrólidos en atención primaria?, Aten Primaria, 25, 375, 10.1016/S0212-6567(00)78525-8
Gisbert, 2000, Recomendaciones de la Conferencia Española de Consenso, Med Clin (Barc), 114, 185, 10.1016/S0025-7753(00)71237-1
1997, The European Helicobacter PyloriStudy Group. Current European concepts in management of Helicobacter Pyloriinfection. The Maastricht Consensus Report, Gut, 41, 8, 10.1136/gut.41.1.8
1997, The report of the Digestive Health Initiative International Update Conference on Helicobacter Pylori, Gastroenterology, 13, 4
Breuer, 1999, Cost of diagnosis and treatment of Helicobacter Pylori: when does choosing the treatment regimen based on susceptibility testing become cost effective?, Am J Gastroenterol, 94, 725, 10.1111/j.1572-0241.1999.00943.x
Pérez-Trallero, 1995, Non-endoscopic method to obtain Helicobacter Pylorifor culture, Lancet, 345, 622, 10.1016/S0140-6736(95)90524-3
Mégraud, 1998, Clinical relevance of resistant strains of Helicobacter Pylori: a review of current data, Gut, 43, 61, 10.1136/gut.43.2008.S61
Adamek, 1998, Primary and acquired. Helicobacter Pyloriresistance to clarithromycin, metronidazole and amoxicillin – Influence of treatment outcome, Am J Gastroenterol, 93, 386
Houben, 1999, Randomized trial of omeprazole and larithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or –susceptible Helicobacter Pyloristrains, Aliment Pharmacol Ther, 13, 883, 10.1046/j.1365-2036.1999.00565.x
Moayyedi, 1995, Efficacy and optimum dose of omeprazole in a new 1-week therapy regimen to eradicate Helicobacter Pylori, Eur J Gastroenterol Hepatol, 7, 835
Moayyedi, 1998, Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin and timidazole to eradicate Helicobacter Pylori, J Gastroenterol, 33, 160, 10.1007/s005350050064
Goh, 1997, Comparison of two 1-week low-dose omeprazole thriple therapies – Optimal treatment for Helicobacter Pyloriinfection, Aliment Pharmacol Ther, 11, 1115, 10.1046/j.1365-2036.1997.00248.x
Lerang, 1997, Highly effective twice-daily triple therapies for Helicobacter Pyloriinfection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?, Am J Gastroenterol, 92, 248
Schwartz, 1996, Seven-day triple therapy with lansoprazole, clarithromycin and metronidazole for the cure of Helicobacter Pyloriinfection: a short report, Helicobacter, 1, 251, 10.1111/j.1523-5378.1996.tb00047.x
Miyaki, 1997, Susceptibility of Helicobacter Pyloriisolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan, Aliment Pharmacol Ther, 11, 1131, 10.1046/j.1365-2036.1997.00258.x
Perng, 1998, One-week triple therapy with lansoprazole, clartithromycin and metronidazole to cure Helicobacter Pyloriinfection in peptic ulcer disease in Korea, Dig Dis Sci, 43, 464, 10.1023/A:1018886318740
Chu, 1998, A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter Pylori, Am J Gastroenterol, 93, 1436, 10.1111/j.1572-0241.1998.00458.x
Misiewicz, 1997, One week triple therapy for Helicobacter Pylori: a multicentre compartive study. Lansoprazole Helicobacter Study Group, Gut, 41, 735, 10.1136/gut.41.6.735
Houben, 1999, A systematic review of Helicobacter Pylorieradication therapy-the impact of antimicrobial resistance on eradication rates, Aliment Pharmacol Ther, 13, 1047, 10.1046/j.1365-2036.1999.00555.x
Buckley, 1997, Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance, Dig Dis Sci, 42, 2111, 10.1023/A:1018882804607
Powell, 1995, An effective oneweek Helicobacter Pylorieradication therapy using omeprazole, clarithromycin and metronidazole, Br J Clin Res, 6, 85
Harris, 1996, Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter Pyloriinfection, Aliment Pharmacol Ther, 1, 1005, 10.1046/j.1365-2036.1996.100272000.x
Xia, 1994, Standardisation of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against H. pylori, Antimicrob Agents Chemother, 38, 2357, 10.1128/AAC.38.10.2357
Realdi, 1999, Pretreatment antibiotic resistance in Helicobacter Pyloriinfection: results of three randomized controlled studies, Helicobacter, 4, 106, 10.1046/j.1523-5378.1999.99002.x
Bazzoli, 1998, Evaluation of short-term low dose triple therapy for the eradication of Helicobacter Pyloriby factorial design in a randomized double-blind, controlled study, Aliment Pharmacol Ther, 12, 439, 10.1046/j.1365-2036.1998.00330.x